Table 5 Summary of ibrutinib dose discontinuation rates or modification in clinical trials vs “real-world practice” studies
Clinical trial | Real-world | |
|---|---|---|
Average discontinuation rate due to toxicity | 36.3% (range 13–64.7%) | 45.2% (range 9.7–63.1%) |
Average discontinuation rate due to relapsed disease | 34.2% (range 11.8–50.5%) | 25.5% (range 12.8–53%) |
Average dose reduction over 1 year | 7.3% (range 6–9%) | 20.5% (range 11–31.3%) |